Search by Drug Name or NDC

    NDC 46287-0030-01 ATORVALIQ 20 mg/5mL Details

    ATORVALIQ 20 mg/5mL

    ATORVALIQ is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by CMP Pharma, Inc.. The primary component is ATORVASTATIN CALCIUM TRIHYDRATE.

    Product Information

    NDC 46287-0030
    Product ID 46287-030_6efeeae4-a15b-4a7b-8b10-6930534a92ea
    Associated GPIs
    GCN Sequence Number 084377
    GCN Sequence Number Description atorvastatin calcium ORAL SUSP 20 MG/5 ML ORAL
    HIC3 M4D
    HIC3 Description ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(STATINS)
    GCN 53672
    HICL Sequence Number 012404
    HICL Sequence Number Description ATORVASTATIN CALCIUM
    Brand/Generic Brand
    Proprietary Name ATORVALIQ
    Proprietary Name Suffix n/a
    Non-Proprietary Name ATORVALIQ
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form SUSPENSION
    Route ORAL
    Active Ingredient Strength 20
    Active Ingredient Units mg/5mL
    Substance Name ATORVASTATIN CALCIUM TRIHYDRATE
    Labeler Name CMP Pharma, Inc.
    Pharmaceutical Class HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA213260
    Listing Certified Through 2024-12-31

    Package

    NDC 46287-0030-01 (46287003001)

    NDC Package Code 46287-030-01
    Billing NDC 46287003001
    Package 150 mL in 1 BOTTLE (46287-030-01)
    Marketing Start Date 2023-03-01
    NDC Exclude Flag N
    Pricing Information N/A